Seladelpar - CymaBay Therapeutics

Drug Profile

Seladelpar - CymaBay Therapeutics

Alternative Names: MBX 8025; RWJ 800025

Latest Information Update: 30 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ortho-McNeil
  • Developer CymaBay Therapeutics
  • Class Acetates; Antihyperlipidaemics; Hepatoprotectants
  • Mechanism of Action C-reactive protein inhibitors; Peroxisome proliferator-activated receptor delta agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hyperlipoproteinaemia type V; Hyperlipoproteinaemia type I; Hyperlipoproteinaemia type IIa; Primary biliary cirrhosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Primary biliary cirrhosis
  • Phase II Hyperlipidaemia; Hyperlipoproteinaemia type IIa; Non-alcoholic steatohepatitis

Most Recent Events

  • 15 May 2018 CymaBay Therapeutics completes a phase I trial in Non-alcoholic steatohepatitis in USA (PO) (NCT03369002)
  • 11 May 2018 Phase-II clinical trials in Non-alcoholic steatohepatitis in USA (PO)
  • 08 May 2018 CymaBay Therapeutics plans a phase II trial for Non-alcoholic steatohepatitis in the first half of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top